• 목록
• 답변

Arbormed Co., Ltd. (Co-CEOs Kyo-jin Park and Weon-bin Im) announced on the 29th that it has entered into an additional complex generic sales license agreement, accelerating progress in related business activities.

Complex generics, referring to drugs that are challenging to manufacture and develop, have a limited product count, approximately five in this case. Penmix is a CDMO pharmaceutical company specializing in injectable finished drugs, supplying such drugs to numerous global pharmaceutical companies in Europe, Japan, the Middle East, and Southeast Asia. Penmix possesses advanced capabilities in finished drug development and manufacturing. In 2022, Penmix's sterile injection factory obtained EU-GMP, with plans to acquire US cGMP in 2025.

Arbormed aims to promptly seek sales approval from the U.S. Food and Drug Administration (FDA) following the signing of an exclusive distribution rights agreement with Penmix Co., Ltd. for Sugammadex and Ferric Calboxymaltose in the United States. Under this agreement, Arbormed gains exclusive rights for commercialization in the U.S., while Penmix assumes roles in clinical development, manufacturing, and supply.

Consequently, Arbormed secures exclusive distribution rights in the U.S. for six products previously signed with Korea United Pharmaceutical, iCure, PTS in the U.S., and ETICO in India. Additionally, exclusive U.S. distribution rights are obtained for two complex generic products currently in development by Penmix, bringing the total to eight items under complex generic copyright.

Park Kyo-jin, CEO of Arbormed, said, “We are very pleased to have signed this contract with Penmix.” He added, “Through this contract, Penmix’s major product lines, our company’s experience and know-how in the U.S. pharmaceutical market, and our human network capabilities will help create a positive relationship between the two companies.” “We expect that synergy will be maximized.”

He continued, “In particular, in the case of Ferric Calboxymaltose, the market size is approximately 1.3 trillion won, and when entering the market in the future, sales of more than 50 billion won and a net profit of about 20% are expected to be expected, so both companies have very high expectations. “He added, “As the complex generic market is expected to gradually expand, we are planning to secure a pipeline by continuously signing sales rights contracts.”